Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK-guided Kovaltry prophylaxis in Chinese children with severe hemophilia A
ChiCTR2000037821Phase 4Not yet recruiting
- Sponsor
- Beijing Children's Hospital
- Start
- Jan 2021
- Modality
- Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of rurioctocog alfa pegol in hemophilia A, sponsored by Beijing Children's Hospital. Primary endpoints: Pharmacokinetic profiles, Annual bleeding rate and 5 more. Planned start Jan 2021; status: not yet recruiting.
02
Drugs
rurioctocog alfa pegol
03
Conditions
hemophilia A
Beyond the preview
Go deeper on ChiCTR2000037821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000037821.